Note: This medical device record is a PMA supplement. A supplement may have changed the device description/function or indication from that approved in the original PMA. Be sure to look at the original PMA record for more information. |
|
Device | FoundationOne CDx, FoundationOne Liquid CDx |
Generic Name | Next generation sequencing oncology panel, somatic or germline variant detection system |
Applicant | Foundation Medicine, Inc. 150 Second Street, 1st Floor Cambridge, MA 02141 |
PMA Number | P170019 |
Supplement Number | S022 |
Date Received | 11/27/2020 |
Decision Date | 07/21/2021 |
Product Code |
PQP |
Advisory Committee |
Pathology |
Supplement Type | Real-Time Process |
Supplement Reason | Labeling Change - Indications/instructions/shelf life/tradename |
Expedited Review Granted? | No |
Combination Product | No |
Approval Order Statement Approval for the variant classification procedure to add additional variants to existing BRCA1, BRCA2 and ATM companion diagnostic claims for PARP inhibitors (e.g., rucaparib and olaparib) on FoundationOne CDx and FoundationOne Liquid CDx |
|
|